

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CLINUVEL PHARMACEUTICALS LTD
ABN	88 089 644 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stan McLiesh
Date of last notice	23 January 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect Interest (Ordinary Shares) Direct Interest (Unlisted Conditional Performance Rights)
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary shares held on behalf of Director by the Clinuvel Conditional Performance Rights Scheme Trust (Registered Holder : ACN 108 768 896 PTY LTD)
Date of change	03 August 2016
No. of securities held prior to change	191,000 Ordinary Shares (includes 115,000 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust) 85,000 Unlisted Conditional Performance Rights
Class	Ordinary Shares
Number acquired	20,000 Ordinary Shares
Number disposed	20,000 Unlisted Conditional Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$nil

No. of securities held after change	211,000 Ordinary Shares (includes 135,000 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust) 65,000 Unlisted Conditional Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Unlisted Conditional Performance Rights ('Rights') under the company's Performance Rights Plan upon achievement of a performance condition, the issue of Rights to the Director as approved by shareholders at the Company's 2014 Annual General Meeting

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	13 July 2016

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CLINUVEL PHARMACEUTICALS LTD
ABN	88 089 644 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philippe Wolgen
Date of last notice	23 January 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect Interest (Ordinary Shares) Direct Interest (Unlisted Conditional Performance Rights)
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary shares held on behalf of Director by the Clinuvel Conditional Performance Rights Scheme Trust (Registered Holder : ACN 108 768 896 PTY LTD)
Date of change	03 August 2016
No. of securities held prior to change	2,079,832 Ordinary Shares (includes 1,974,946 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust) 1,424,864 Unlisted Conditional Performance Rights
Class	Ordinary Shares
Number acquired	499,890 Ordinary Shares
Number disposed	499,890 Unlisted Conditional Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$Nil

No. of securities held after change	2,579,722 Ordinary Shares (includes 2,474,836 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust) 924,974 Unlisted Conditional Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Unlisted Conditional Performance Rights ('Rights') under the company's Performance Rights Plan upon achievement of a performance condition, the issue of Rights to the Director as approved by shareholders at the Company's 2014 Annual General Meeting

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	13 July 2016

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CLINUVEL PHARMACEUTICALS LTD
ABN	88 089 644 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Elie Ishag
Date of last notice	23 January 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect Interest (Ordinary Shares) Direct Interest (Ordinary Shares) Direct Interest (Unlisted Conditional Performance Rights)
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	1. Ordinary shares held by Euro Investments & Developments S.A. (beneficiary) 2. Ordinary shares held on behalf of Director by the Clinuvel Conditional Performance Rights Scheme Trust (Registered Holder : ACN 108 768 896 PTY LTD)
Date of change	03 August 2016
No. of securities held prior to change	49,104 Ordinary Shares (Direct) 35,591 Ordinary Shares (Indirect - Euro Investments & Developments S.A (beneficiary)) 63,500 Ordinary Shares (Indirect - Clinuvel Conditional Performance Rights Scheme Trust) 56,500 Unlisted Conditional Performance Rights (Direct)
Class	Ordinary Shares
Number acquired	14,000 Ordinary Shares
Number disposed	14,000 Unlisted Conditional Performance Rights
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$Nil

No. of securities held after change	49,104 Ordinary Shares (Direct) 35,591 Ordinary Shares (Indirect - Euro Investments & Developments S.A (beneficiary)) 77,500 Ordinary Shares (Indirect - Clinuvel Conditional Performance Rights Scheme Trust 42,500 Unlisted Conditional Performance Rights (Direct)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Unlisted Conditional Performance Rights ('Rights') under the company's Performance Rights Plan upon achievement of a performance condition , the issue of Rights to the Director as approved by shareholders at the Company's 2014 Annual General Meeting

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	13 July 2016

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CLINUVEL PHARMACEUTICALS LTD
ABN	88 089 644 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brenda Shanahan
Date of last notice	23 January 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect Interest (Ordinary Shares) Direct Interest (Unlisted Conditional Performance Rights)
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"> San Luis Nominees Pty Ltd (trustee for the Brenda Shanahan Superannuation Fund) Ordinary shares held on behalf of Director by the Clinuvel Conditional Performance Rights Scheme Trust (Registered Holder : ACN 108 768 896 PTY LTD)
Date of change	03 August 2016
No. of securities held prior to change	<ol style="list-style-type: none"> 53,969 Ordinary Shares (San Luis Nominees Pty Ltd) 80,000 Ordinary shares (Clinuvel Conditional Performance Rights Scheme Trust) 70,000 Unlisted Conditional Performance Rights
Class	Ordinary Shares
Number acquired	20,000 Ordinary Shares
Number disposed	20,000 Unlisted Conditional Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$Nil

No. of securities held after change	3. 53,969 Ordinary Shares (San Luis Nominees Pty Ltd) 4. 100,000 Ordinary shares (Clinuvel Conditional Performance Rights Scheme Trust) 50,000 Unlisted Conditional Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Unlisted Conditional Performance Rights ('Rights') under the company's Performance Rights Plan upon achievement of a performance condition , the issue of Rights to the Director as approved by shareholders at the Company's 2014 Annual General Meeting

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	13 July 2016